Optimum timing of lung resection surgery following SARS-CoV-2 infection for non-small cell lung cancer
© 2023 The Authors. Cancer Medicine published by John Wiley & Sons Ltd..
BACKGROUND: The impact of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection on postoperative recovery of non-small cell lung cancer (NSCLC) is need to be understood, thereby informing the optimal timing of surgical decision-making during the COVID-19 pandemic for NSCLC patients. This study reports the postoperative outcomes of surgical NSCLC patients with preoperative SARS-CoV-2 infection.
METHOD: This single-center retrospective cohort study included 241 NSCLC patients who underwent lobectomy or sub-lobectomy between December 1, 2022 and February 14, 2023. Surgical outcomes of patients with preoperative SARS-CoV-2 infection (stratified by the time from diagnosis of SARS-CoV-2 infection to surgery) were compared with those without preoperative SARS-CoV-2 infection. The primary outcomes were total postoperative complications and postoperative pulmonary complications (PPCs), the secondary outcomes included operation time, total postoperative drainage and time, length of hospital stay (LOS), 30-day and 90-day postoperative symptoms.
RESULTS: This study included 153 (63.5%) patients with preoperative SARS-CoV-2 infection and 88 (36.5%) patients without previous SARS-CoV-2 infection. In patients with a preoperative SARS-CoV-2 diagnosis, the incidence of total postoperative complications (OR, 3.00; 95% CI, 1.12-8.01; p = 0.028) and PPCs (OR, 4.20; 95% CI, 1.11-15.91; p = 0.035) both increased in patients infected having surgery within 2 weeks compared with non-infection before surgery. However, patients who underwent lung resection more than 2 weeks after SARS-CoV-2 diagnosis had a similar risk of postoperative complications and surgical outcomes with those non-infection before surgery.
CONCLUSION: This is the first study to provide evidence regarding the optimum timing of lung resection surgery and assessing early outcomes after surgery in NSCLC patients with SARS-CoV-2 infection. Our study documents that the SARS-CoV-2 infection did not complicate surgical procedures for lung cancer, and suggest that lung surgery should be postponed at least 2 weeks after SARS-CoV-2 infection for NSCLC patients.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - year:2024 |
|---|---|
| Enthalten in: |
Cancer medicine - (2024) vom: 02. Jan. |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Yang, Yanbo [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Coronavirus disease 2019 (COVID-19) |
|---|
| Anmerkungen: |
Date Revised 26.01.2024 published: Print-Electronic Citation Status Publisher |
|---|
| doi: |
10.1002/cam4.6891 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM366597868 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM366597868 | ||
| 003 | DE-627 | ||
| 005 | 20240126232109.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240108s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1002/cam4.6891 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1271.xml |
| 035 | |a (DE-627)NLM366597868 | ||
| 035 | |a (NLM)38169158 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Yang, Yanbo |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Optimum timing of lung resection surgery following SARS-CoV-2 infection for non-small cell lung cancer |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 26.01.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status Publisher | ||
| 520 | |a © 2023 The Authors. Cancer Medicine published by John Wiley & Sons Ltd. | ||
| 520 | |a BACKGROUND: The impact of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection on postoperative recovery of non-small cell lung cancer (NSCLC) is need to be understood, thereby informing the optimal timing of surgical decision-making during the COVID-19 pandemic for NSCLC patients. This study reports the postoperative outcomes of surgical NSCLC patients with preoperative SARS-CoV-2 infection | ||
| 520 | |a METHOD: This single-center retrospective cohort study included 241 NSCLC patients who underwent lobectomy or sub-lobectomy between December 1, 2022 and February 14, 2023. Surgical outcomes of patients with preoperative SARS-CoV-2 infection (stratified by the time from diagnosis of SARS-CoV-2 infection to surgery) were compared with those without preoperative SARS-CoV-2 infection. The primary outcomes were total postoperative complications and postoperative pulmonary complications (PPCs), the secondary outcomes included operation time, total postoperative drainage and time, length of hospital stay (LOS), 30-day and 90-day postoperative symptoms | ||
| 520 | |a RESULTS: This study included 153 (63.5%) patients with preoperative SARS-CoV-2 infection and 88 (36.5%) patients without previous SARS-CoV-2 infection. In patients with a preoperative SARS-CoV-2 diagnosis, the incidence of total postoperative complications (OR, 3.00; 95% CI, 1.12-8.01; p = 0.028) and PPCs (OR, 4.20; 95% CI, 1.11-15.91; p = 0.035) both increased in patients infected having surgery within 2 weeks compared with non-infection before surgery. However, patients who underwent lung resection more than 2 weeks after SARS-CoV-2 diagnosis had a similar risk of postoperative complications and surgical outcomes with those non-infection before surgery | ||
| 520 | |a CONCLUSION: This is the first study to provide evidence regarding the optimum timing of lung resection surgery and assessing early outcomes after surgery in NSCLC patients with SARS-CoV-2 infection. Our study documents that the SARS-CoV-2 infection did not complicate surgical procedures for lung cancer, and suggest that lung surgery should be postponed at least 2 weeks after SARS-CoV-2 infection for NSCLC patients | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a coronavirus disease 2019 (COVID-19) | |
| 650 | 4 | |a non-small cell lung cancer (NSCLC) | |
| 650 | 4 | |a optimum timing | |
| 650 | 4 | |a severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) | |
| 650 | 4 | |a surgical outcome | |
| 700 | 1 | |a Niu, Lingli |e verfasserin |4 aut | |
| 700 | 1 | |a Zhu, Yunke |e verfasserin |4 aut | |
| 700 | 1 | |a Wu, Zhu |e verfasserin |4 aut | |
| 700 | 1 | |a Xia, Liang |e verfasserin |4 aut | |
| 700 | 1 | |a Xiao, Congjia |e verfasserin |4 aut | |
| 700 | 1 | |a Shen, Xu |e verfasserin |4 aut | |
| 700 | 1 | |a Xiao, Xin |e verfasserin |4 aut | |
| 700 | 1 | |a Tian, Conglin |e verfasserin |4 aut | |
| 700 | 1 | |a Lin, Feng |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Cancer medicine |d 2012 |g (2024) vom: 02. Jan. |w (DE-627)NLM224388460 |x 2045-7634 |7 nnns |
| 773 | 1 | 8 | |g year:2024 |g day:02 |g month:01 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1002/cam4.6891 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |j 2024 |b 02 |c 01 | ||